Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ecabet ophthalmic solution
Ecabet · 2 trials · 2 indications
The Schirmer's test is used determine if tear glands produce enough tears to keep eyes adequately moist. Calibrated strips of a non-toxic filter paper are used. One free end is placed within the lower eyelid. At the conclusion of the test, the paper strip is removed from the lower eyelid and the amount of wetting of the paper strip is measured.
ocular signs, including corneal and conjunctival staining, tear film breakup time and blink rate, and ocular symptoms, including burning or stinging, itchiness or scratchiness, grittiness or sandiness, foreign body sensation, haziness or blurriness, photophobia, photopsia, and eye discomfort
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | ecabet ophthalmic solution |
| 2 | PLACEBO_COMPARATOR | Placebo comparator |
| Ecabet | EXPERIMENTAL | Ophthalmic solution in the Study eye four times daily for 90 days. |
| Placebo | PLACEBO_COMPARATOR | Ophthalmic solution in the Study eye four times daily for 90 days. |
| Name | Type | Description |
|---|---|---|
| ecabet ophthalmic solution | DRUG | sterile ophthalmic solution |
| placebo | DRUG | sterile ophthalmic solution |
| Ecabet | DRUG | ophthalmic solution 2.83% |
Inclusion Criteria: * Diagnosed with dry eye disease Exclusion Criteria: * Dry eye disease secondary to surgery
Top 4 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | VSJ-110 |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | ABBV-319 |
| Oculis Holding AG | OCS | 1 | PHASE2 | licaminlimab |
| Bausch Health Companies Inc. | BHC | 1 | PHASE2 | BL1107 |
Ecabet is being developed for Dry Eye Disease and Dry Eye Syndromes. It is an ophthalmic solution intended for topical use in the eye. The clinical program has focused on evaluating its efficacy in treating these tear film and ocular surface conditions.
Ecabet is being developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company is responsible for the clinical development of the ecabet ophthalmic solution for dry eye indications.
Ecabet is in Phase 2 clinical development. It has not been approved by the FDA and remains an investigational product. The completed Phase 2 trials were designed to assess efficacy and safety in patients with dry eye conditions.
Ecabet has been studied in two completed Phase 2 trials: NCT00667004, titled Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease, and NCT00370747, titled Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome. Both were conducted in the United States.
Yes, ecabet ophthalmic solution is another name for Ecabet. The term refers to the same investigational product developed by Bausch + Lomb for dry eye indications. Searches for either name refer to the same clinical program.
The two completed Phase 2 trials of Ecabet enrolled a combined total of 345 patients. NCT00667004 enrolled 183 participants, and NCT00370747 enrolled 162 participants. Both studies were randomized, double-blind, and placebo-controlled, and included adults aged 18 years and older.